Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Open-Label Study of IMM 101 with Standard Chemotherapy in Metastatic or Unresectable Cancer
2016-001459-28Phase 2Terminated
- Sponsor
- Immodulon Therapeutics
- Start
- Sep 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM-101 in metastasis and cancer, sponsored by Immodulon Therapeutics. Primary endpoint: Safety and tolerability. Started Sep 2016; status: terminated.
02
Drugs
IMM-101
03
Conditions
metastasiscancer
Beyond the preview
Go deeper on 2016-001459-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001459-28.